Interested in an Exhibit Hall & Keynote Pass?
Sign up to be informed by email as soon as Exhibit Hall & Keynote passes are available.
» Sign up
Did You Know?
- North Carolina has the nation's third largest biotech industry for four years in a row, according to Ernst & Youngs 2007 global industry survey, Beyond Borders.
- More than 50 companies manufacturing biologics, pharmaceuticals and diagnostics already call North Carolina home. These companies -- Biogen Idec, GlaxoSmithKline, Novozymes, Pfizer Animal Health, Talecris, and Wyeth -- operate some of the largest or most unique facilities of their kind.
Develop Valuable Partnerships and Gain a Competitive Advantage for Continuous Improvement
The biopharmaceutical industry has embraced the BioProcess International™ Conference and Exhibition as its premier event. BPI is your key to a week of intensive learning, evocative discussions, enjoyable networking and solutions to your service, equipment and raw materials needs. This is the one place where you know you will have the opportunity to meet with the key players in the field.
From high-level strategy to nuts and bolts technical case studies, the program digs deep into important areas where regulatory, technical and market forces are changing the field. Whether you work with mAbs, recombinant proteins, vaccines, or other types of biologics - at a large or small company - here you will find presentations and discussions which will answer your specific information requirements.
4 Comprehensive Tracks
Keynote Presentations
Reinventing Biologics Pharmaceutical Development and Marketed Product Support
Paul F. McKenzie Vice President, BIO Pharmaceutical Development and Marketed Product Support, Centocor R&D
|
ObamaCare: Stimulus Spending, System Reform and Market Change
J.D. Kleinke Medical Economist and Author, Oxymorons: The Myth of a U.S. Health Care System
|
Future Trends in Biopharmaceutical Operations and Facilities
Johannes Roebers, Ph.D. Senior Vice President, Head of Biologic Strategy, Planning & Operations, Elan Pharma International Limited, Ireland
|
Operational Excellence: The Opportunity in the Life Sciences Industry
G.K. Raju, Ph.D. Executive Director, Manufacturing Initiatives, MIT Center for Biomedical Innovations
|
Integrating New Technologies in Upstream and Downstream Processing
Konstantin Konstantinov, Ph.D. Vice President, Technology Development, Genzyme Corp.
|
In Pursuit of Quality: Continual Improvement, Innovation, and Regulatory Oversight
Ali M. Afnán, Ph.D. Senior Staff Fellow, OPS, CDER, US FDA
|
BPI is Your Best Resource to Hear Industry Leaders Deliver Insights on:
- Fostering the Integration of Upstream and Downstream Processing
- Planning for Disruptive Technologies
- Minimizing Risk through Management Strategies and Analytical Technologies
- "Nuts and Bolts" of Implementing Quality by Design
- Using Scale-Down Models to Solve Large-Scale Problems
Expanded By Popular Demand
9
Strategic Discussion Forums
Providing You Invaluable and Uncensored Insight on the Industry's Most Pressing Challenges
- A Call for Industrializing Biomanufacturing: What is Being Done About It?
- Plant Capacity: Successful Strategies to Deal with Too Much of it
- Defining Animal-Free for Cell Culture-Based Biotherapeutic Production
- BioSMB™: Open Platform, Fully Disposable, Continuous Downstream Processing
- Adopting New Technology – Take II
- Flexible, Small Scale Manufacturing Facility Scenarios
- Measurement Uncertainty: Acknowledging, Analyzing, and Managing
- Process Validation for the 21st Century
- Navigating the Pathway to Regulatory Approval from Phase I to PAI